Relevance to other NICE programmes

Relevance to other NICE programmes

The use of adjuvant bisphosphonates for preventing recurrence and improving survival in early breast cancer is not appropriate for referral for a NICE technology appraisal and is not currently planned into any other work programme.

NICE has issued the following guidance relating to early breast cancer:

A NICE interactive flowchart on early and locally advanced breast cancer and a quality standard on breast cancer (2011; updated 2016) are also available.

The following NICE guidance relates to licensed indications for bisphosphonates:

As well as guidance, NICE produces advice publications which do not constitute formal NICE guidance but critically appraise the evidence to help decision-making. These include: